EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSBTAG00000012296
Gene Symbol: GABRG1
5 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSBTAG00000010251
Gene Symbol: GABRG2
4 Enzyme and pathways 5 Cross references
218 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSBTAG00000052298
Gene Symbol: GABRG3
4 Enzyme and pathways 2 Cross references
251 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Pi

Ensembl ID : ENSBTAG00000002779
Gene Symbol: GABRP
5 Cross references
137 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Theta

Ensembl ID : ENSBTAG00000013002
Gene Symbol: GABRQ
4 Enzyme and pathways 5 Cross references
98 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSBTAG00000017239
Gene Symbol: GABBR1
17 Enzyme and pathways 5 Cross references
279 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSBTAG00000013810
Gene Symbol: GABBR2
17 Enzyme and pathways 5 Cross references
220 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSBTAG00000005527
Gene Symbol: GIPR
7 Enzyme and pathways 5 Cross references
103 Possible Orthologues:

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSBTAG00000018224
Gene Symbol: GLP1R
11 Enzyme and pathways 5 Cross references
145 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSBTAG00000005052
Gene Symbol: GLP2R
7 Enzyme and pathways 5 Cross references
217 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSBTAG00000003786
Gene Symbol: GCGR
11 Enzyme and pathways 5 Cross references
195 Possible Orthologues:

Glucokinase

Ensembl ID : ENSBTAG00000032288
Gene Symbol: GCK
5 Enzyme and pathways 5 Cross references
227 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).